Inference of drug off-target effects on cellular signaling using interactome-based deep learning

被引:1
|
作者
Meimetis, Nikolaos [1 ]
Lauffenburger, Douglas A. [1 ]
Nilsson, Avlant [1 ,2 ,3 ]
机构
[1] MIT, Dept Biol Engn, Cambridge, MA 02139 USA
[2] Karolinska Inst, Dept Cell & Mol Biol, SciLifeLab, Stockholm, Sweden
[3] Chalmers Univ Technol, Dept Biol & Biol Engn, SE-41296 Gothenburg, Sweden
基金
瑞典研究理事会;
关键词
CANCER; DYSREGULATION; PHARMACOLOGY; MECHANISMS; DISCOVERY; BIOLOGY; FOXM1C;
D O I
10.1016/j.isci.2024.109509
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many diseases emerge from dysregulated cellular signaling, and drugs are often designed to target specific signaling proteins. Off -target effects are, however, common and may ultimately result in failed clinical trials. Here we develop a computer model of the cell's transcriptional response to drugs for improved understanding of their mechanisms of action. The model is based on ensembles of artificial neural networks and simultaneously infers drug -target interactions and their downstream effects on intracellular signaling. With this, it predicts transcription factors' activities, while recovering known drug -target interactions and inferring many new ones, which we validate with an independent dataset. As a case study, we analyze the effects of the drug Lestaurtinib on downstream signaling. Alongside its intended target, FLT3, the model predicts an inhibition of CDK2 that enhances the downregulation of the cell cycle -critical transcription factor FOXM1. Our approach can therefore enhance our understanding of drug signaling for therapeutic design.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] Prediction of on-target and off-target activity of CRISPR-Cas13d guide RNAs using deep learning
    Wessels, Hans-Hermann
    Stirn, Andrew
    Mendez-Mancilla, Alejandro
    Kim, Eric J.
    Hart, Sydney K.
    Knowles, David A.
    Sanjana, Neville E.
    NATURE BIOTECHNOLOGY, 2024, 42 (04) : 628 - 637
  • [32] Off-target profiles of drugs using ligand-based target fishing
    AbdulHameed, Mohamed Diwan M.
    Chaudhury, Sidhartha
    Singh, Narender
    Sun, Hongmao
    Wallqvist, Anders
    Tawa, Gregory
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [33] Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches
    Cheng, Xiaolong
    Li, Zexu
    Shan, Ruocheng
    Li, Zihan
    Wang, Shengnan
    Zhao, Wenchang
    Zhang, Han
    Chao, Lumen
    Peng, Jian
    Fei, Teng
    Li, Wei
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [34] Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches
    Xiaolong Cheng
    Zexu Li
    Ruocheng Shan
    Zihan Li
    Shengnan Wang
    Wenchang Zhao
    Han Zhang
    Lumen Chao
    Jian Peng
    Teng Fei
    Wei Li
    Nature Communications, 14
  • [36] Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
    Kuenzi, Brent M.
    Rix, Lily L. Remsing
    Kinose, Fumi
    Kroeger, Jodi L.
    Lancet, Jeffrey E.
    Padron, Eric
    Rix, Uwe
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [37] Using traditional machine learning and deep learning methods for on- and off-target prediction in CRISPR/Cas9: a review
    Sherkatghanad, Zeinab
    Abdar, Moloud
    Charlier, Jeremy
    Makarenkov, Vladimir
    BRIEFINGS IN BIOINFORMATICS, 2023, 24 (03)
  • [38] Reporting off-target effects of recombinant engineering using the pORTMAGE system
    Sanders, Brittany R.
    Townsend, Sydney E.
    Ford, Maria L.
    Graves, Joseph L.
    Thomas, Misty D.
    JOURNAL OF MICROBIOLOGICAL METHODS, 2023, 204
  • [39] Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
    Kuenzi, Brent M.
    Rix, Lily L. Remsing
    Kunigal, Sateesh S.
    Kinose, Fumi
    Knezevic, Claire E.
    Wright, Gabriela
    Kroeger, Jodi L.
    Lancet, Jeffrey E.
    Padron, Eric
    Rix, Uwe
    CANCER RESEARCH, 2015, 75
  • [40] Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
    Brent M. Kuenzi
    Lily L. Remsing Rix
    Fumi Kinose
    Jodi L. Kroeger
    Jeffrey E. Lancet
    Eric Padron
    Uwe Rix
    Scientific Reports, 9